Peer-reviewedCC BY-NC-NDTranslational Lung Cancer Research
Synergistic effects and molecular mechanisms of pirfenidone combined with EGFR-TKIs in non-small cell lung cancer
- 1Department of Respiratory and Critical Care Medicine , Institute of Respiratory Health , Frontiers Science Center for Disease-related Molecular Network , West China Hospital , Sichuan University , Chengdu , ;
- 2Division of Abdominal Tumor Multimodality Treatment , Cancer Center and Laboratory of Abdominal Tumor Immunology and Microenvironment , West China Hospital , Sichuan University , Chengdu ,
Related
- Synergistic antitumor effects of combined pembrolizumab and anlotinib via EGFR inhibition and tumor microenvironment remodeling in high-grade serous ovarian cancer
- Molecular mechanisms for sustaining cancer stem cells characteristics and targeted therapeutic strategies
- Molecular Mechanisms and Therapeutic Advances in KRAS G12C‐Mutant Non‐Small Cell Lung Cancer: Toward Mechanism‐Guided Longitudinal Management
- Prophylactic pirfenidone to prevent radiation- induced lung injury in ICI-pretreated lung cancer patients: a phase II study
- Special Issue “Molecular Mechanisms and Therapies of Pancreatic Cancer: 2nd Edition”
BibTeX
@article{tang2026synergistic,
title = {{Synergistic effects and molecular mechanisms of pirfenidone combined with EGFR-TKIs in non-small cell lung cancer}},
author = {Pan Tang and Chen Huang and Fengmei Zhang and Jiayi Li and Weimin Li and Chenliang Zhang and Zhoufeng Wang},
journal = {Translational Lung Cancer Research},
year = {2026},
month = aug,
url = {https://europepmc.org/article/PMC/PMC13657879},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Synergistic effects and molecular mechanisms of pirfenidone combined with EGFR-TKIs in non-small cell lung cancer
AU - Pan Tang
AU - Chen Huang
AU - Fengmei Zhang
AU - Jiayi Li
AU - Weimin Li
AU - Chenliang Zhang
AU - Zhoufeng Wang
PY - 2026
DA - 2026/08/28
JO - Translational Lung Cancer Research
UR - https://europepmc.org/article/PMC/PMC13657879
SN - 2218-6751
ER -